Ice age baby Albee was born with a congenital heart defect.
Now, the world’s oldest baby with a heart defect could be the next in line.
A team of scientists from MIT and the University of Pennsylvania have been working on a new gene therapy that might be able to restore Albee’s heart.
The team plans to test it on a single baby.
The baby has an extra gene called an ALD1 gene that encodes a protein that protects against heart attacks.
The protein, ALD-1, was first discovered in the 1930s by German scientist Hermann von Braun.
Albee, the baby with the defect, was born in the same year, and was the first human with this defect.
Scientists are hopeful that Albee will have a better chance of surviving heart attacks and cancer.
They hope that the gene therapy might be developed to be used in patients with congenital defects.
Albees genetic makeup was different.
Scientists were able to develop a new blood test to detect ALD 1 in his blood before he was born.
They are now developing a gene therapy to correct this mutation.
The new gene has a longer half-life, meaning that if Albee is implanted in the future, he could live a long time.
“If we have to stop the gene from going into the baby, the risk of cancer is going to be a lot higher,” said Andrew Schuster, a researcher at the University College London, in a press release.
The researchers hope that this new gene will be used to target cancer-related mutations.
Schuster said that in some cases, cancer cells might be more resistant to the gene than normal cells.
The ALD gene mutation is not the only reason why Albee might not be able.
Albeys heart can still beat normally.
“Albee’s genome was completely different from what’s found in humans,” Schuster told Engadet.
Alabeys heart has a different type of heart muscle that is known as the pacemaker muscle.
The heart muscle is the pump that pumps blood to the lungs.
Scientists have discovered that the pacemakers are part of the immune system of the body.
They also discovered that it is possible for cells to survive in Albees heart without the need for a pacemaker.
“We’re very hopeful that this gene therapy will be able, at the very least, to stop Albee from being born prematurely,” said Schuster.
The scientists hope that their gene therapy could be used for the treatment of other defects as well.
Alba, the gene is used to repair a genetic mutation in the body that causes a genetic defect in a gene called APOE.
In other words, a baby with one copy of the gene mutation that is inherited from his or her mother could have one copy that is found in people with different APOE genotypes.
This gene is also found in a variety of diseases.
For example, the mutation can cause congenital arteriosclerosis in children, which can lead to heart problems later in life.
“This mutation, which was passed down to Albee through the family, was responsible for his heart defect,” Schusters said.
The gene therapy is a small molecule that has not been used before in humans.
It has only been tested on a few human embryos.
Schusters hopes that more children with the mutation will be tested.
If the gene treatment works, he said, “it could be one of the first steps towards treating the disease.”
Albee also had a genetic condition called cystic fibrosis.
This condition causes the lungs to be damaged by inflammation.
Albie was diagnosed with this condition in the womb.
Scientists believe that the genetic mutation was passed on from his mother, who had a cystic lung disease, and the baby inherited this mutation as well from his father.
Albin’s family also had cystic lungs.
He also has a genetic disorder called Tay-Sachs, which causes cystic blood vessels to become damaged in the arteries.
This can cause blood clots and block the flow of blood to organs, which could lead to cardiac arrest.
Albi’s genetic condition also caused him to have problems with the heart.
It caused him chest pains, dizziness, and weakness.
The doctors have tested Albee and his mother’s blood for a gene that has a similar mutation to that found in Tay-SAChs.
They found that Albie has an abnormally high level of ALD 2.
This abnormality is associated with the accumulation of abnormal levels of a protein called ALD2 in the cells of the lungs, which is one of several proteins that are responsible for the immune response.
Researchers believe that ALD deficiency in humans could be a contributing factor to the development of heart disease.
“It is known that a deficiency in one or more of these proteins is associated in some patients with cardiovascular disease,” said Dr. Scott M. Davis, the chief medical officer for the American Heart Association, in an interview with Eng